AdipoGen Life Sciences

GNE-493

Product Code:
 
SYN-1115
Product Group:
 
Inhibitors and Activators
Regulatory Status:
 
RUO
Shipping:
 
-20°C
1 / 1
Chemical Structure
❮❯

Chemical Structure

No additional charges, what you see is what you pay! *

CodeSizePrice
SYN-1115-M100100 mgEnquire
Quantity:
SYN-1115-M05050 mgEnquire
Quantity:
SYN-1115-M0011 mg£233.00
Quantity:
SYN-1115-M0055 mg£461.00
Quantity:
SYN-1115-M01010 mg£643.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Related Products
  • Show All

Further Information

Alternate Names/Synonyms:
GNE493
Appearance:
Solid.
CAS:
1033735-94-2
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C17H20N6O2S/c1-17(2,24)12-7-11-13(26-12)15(23-3-5-25-6-4-23)22-14(21-11)10-8-19-16(18)20-9-10/h7-9,24H,3-6H2,1-2H3,(H2,18,19,20)
InChiKey:
LEXMMFPAPDGYGZ-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1033735-94-2. Formula: C17H20N6O2S. MW: 372.4. GNE-493 is a potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer.
Molecular Formula:
C17H20N6O2S
Molecular Weight:
372.4
Package Type:
Plastic Vial
Product Description:
GNE-493 is a potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.

References

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer: D.P. Sutherlin, et al.; J. Med. Chem. 53, 1086 (2010) | Rational design of phosphoinositide 3-kinase alpha inhibitors that exhibit selectivity over the phosphoinositide 3-kinase beta isoform: T.P. Heffron, et al.; J. Med. Chem. 54, 7815 (2011)